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ABSTRACT
Objective We investigated the mutational landscape of
mammalian target of rapamycin (mTOR) signalling
cascade in hepatocellular carcinomas (HCCs) with
chronic HBV background, aiming to evaluate and
delineate mutation-dependent mechanism of mTOR
hyperactivation in hepatocarcinogenesis.
Design We performed next-generation sequencing on
human HCC samples and cell line panel. Systematic
mutational screening of mTOR pathway-related genes
was undertaken and mutant genes were evaluated
based on their recurrence. Protein expressions of
tuberous sclerosis complex (TSC)1, TSC2 and pRPS6
were assessed by immunohistochemistry in human HCC
samples. Rapamycin sensitivity was estimated by colony-
formation assay in HCC cell lines and the treatment was
further tested using our patient-derived tumour xenograft
(PDTX) models.
Results We identiﬁed and conﬁrmed multiple mTOR
components as recurrently mutated in HBV-associated
HCCs. Of signiﬁcance, we detected frequent (16.2%,
n=18/111) mutations of TSC1 and TSC2 genes in the
HCC samples. The spectrum of TSC1/2 mutations likely
disrupts the endogenous gene functions in suppressing
the downstream mTOR activity through different
mechanisms and leads to more aggressive tumour
behaviour. Mutational disruption of TSC1 and TSC2 was
also observed in HCC cell lines and our PDTX models.
TSC-mutant cells exhibited reduced colony-forming ability
on rapamycin treatment. With the use of biologically
relevant TSC2-mutant PDTXs, we demonstrated the
therapeutic beneﬁts of the hypersensitivity towards
rapamycin treatment.
Conclusions Taken together, our ﬁndings suggest the
signiﬁcance of previously undocumented mutation-
dependent mTOR hyperactivation and frequent TSC1/2
mutations in HBV-associated HCCs. They deﬁne a
molecular subset of HCC having genetic aberrations in
mTOR signalling, with potential signiﬁcance of effective
speciﬁc drug therapy.
INTRODUCTION
Liver cancer (hepatocellular carcinoma (HCC)) is a
major malignancy worldwide and the second most
common fatal cancer in China, including Hong
Kong and Southeast Asia. About 55% of all new
cases worldwide occur in China.1 2 Chronic HBV
infection is the major underlying risk factor. HCC
is deadly because of high recurrence rate even after
Signiﬁcance of this study
What is already known on this subject?
▸ Hepatocellular carcinoma (HCC) is a common
cancer and leading cause of death worldwide.
▸ HCC is heterogeneous with various risk factors
including viral infection (HBV and HCV),
alcoholism and exposure to aﬂatoxin B1.
▸ Activation of mammalian target of rapamycin
(mTOR) signalling cascade is resulted from
ligand-dependent signals from epidermal growth
factor and insulin-like growth factor signalling.
What are the new ﬁndings?
▸ There are frequent mutational disruptions on
multiple key and canonical components of mTOR
signalling cascade.
▸ Mutation-dependent mechanism is likely to be
another major cause leading to mTOR
hyperactivation.
▸ Tuberous sclerosis complex (TSC)1 and TSC2 are
the most frequently mutated mTOR pathway-
related genes and they collectively deﬁne a novel
molecular subset of human HCCs with more
aggressive tumour behaviours.
▸ Our study signiﬁes personalised therapeutic option
for a novel molecular subset of patients with
susceptible mutant HCC through the inhibition of
mTOR signalling.
How might it impact on clinical practice in
the foreseeable future?
▸ TSC1/2 mutations represent one of the most
frequent single categories of genetic alterations
found in human HCC and mTOR signalling
cascade represents one of the most prominent
therapeutic targets in HCC.
▸ There is frequent mutation-dependent mTOR
hyperactivation, which deﬁnes a novel molecular
subset of human HCC and is likely to be
actionable through inhibition by rapamycin or its
derivatives.
▸ Through perfect combination of both high-
throughput next-generation sequencing-based
mutation screening and patient-derived tumour
xenograft model, our study demonstrates, with
necessary supportive evidence correlating
mutational ﬁndings and drug testing, the
potential personalised treatment on relevant
patients with HCC carrying speciﬁc molecular
alterations.
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surgical resection and frequent metastasis. Unfortunately, the
overall response rate of patients with HCC to chemotherapy is
unsatisfactory due to the highly chemoresistant nature of the
tumour and the toxicity of the chemotherapeutic agents. On the
other hand, Sorafenib, a multiple tyrosine-kinase inhibitor and
the only Food and Drug Administration-approved molecularly
targeted drug for HCC, has demonstrated only a modest sur-
vival beneﬁt in patients with HCC, with the median survival
only 2–3 months longer than the placebo arm in large-scale
trials in both Caucasians and Asians.3 4 There is an urgent need
to identify strategic molecular targets for developing new and
effective molecularly targeted therapy. In this regard, investiga-
tion of the mutational landscape of HCC by next-generation
sequencing (NGS) for novel, recurrently mutated targets with
therapeutic implication would be valuable and would help in
rational designing of personalised treatment strategy for patients
with HCC.
Recent studies have demonstrated phosphoinositide 3-kinase
(PI3K)/protein kinase B (PKB/AKT)/mammalian target of rapamy-
cin (mTOR) signalling pathway to have pivotal role in cancers,
including HCC.5 6 Components of mTOR signalling pathway are
frequently upregulated in human HCCs.7 Activation of mTOR
signalling cascade was believed to be the result of ligand-
dependent signals from epidermal growth factor and insulin-like
growth factor signalling, rather than from a mutation-dependent
mechanism.6 In accordance, reported literature has revealed low
frequency of mutations in mTOR signalling pathway.7
To systematically exploit the mutational landscape of mTOR
signalling cascade in chronic HBV background, we performed
deep NGS-based targeted DNA sequencing (targeted-seq) on
a panel of 81 selected mTOR pathway-related genes using a large
cohort of 95 HBV-associated HCC cases. This initial observation
was further augmented by mutational screening using whole-
exome sequencing (WES) on 16 additional HBV-associated HCC
cases, as well as whole-transcriptome sequencing (WTS) and
Sanger sequencing in a panel of HCC cell lines. We found fre-
quent mutations on various components of mTOR signalling
cascade. Among the mutant mTOR-related genes identiﬁed,
tuberous sclerosis complex (TSC) 1 and TSC2 were found to be
the most frequently mutated in HCC tumour samples. Such fre-
quent mutational disruption of TSC1/2 complex, which plays
negative regulatory on Rheb and in turn inactivates mTORC1
activity, would likely result in hyperactivation of mTOR signalling
as suggested by immunohistochemistry (IHC) staining. Of note,
we further provide the necessary therapeutic implication of TSC
mutations by subjecting relevant TSC-mutant cell lines and
in-house established patient-derived tumour xenograft (PDTX)
models to rapamycin treatment and conﬁrmed their hypersensi-
tivity. Overall, our study supports personalised therapeutic option
for a novel molecular subset of patients with susceptible mutant
HCC, through the inhibition of mTOR signalling.
MATERIALS AND METHODS
Patients and samples
A total of 95 human HCCs were selected from our sample col-
lection to perform deep-targeted-seq. Another 16 pairs of
human HCCs and their corresponding non-tumourous livers
(NTLs) were used in WES. All patients had chronic HBV infec-
tion and were positive for hepatitis B surface antigen in their
sera (see online supplementary table S1). The samples were
obtained immediately after surgical resection from the operation
theatre, frozen in liquid nitrogen and kept at −80°C. Frozen sec-
tions were cut from tumour and NTL blocks separately and
stained for histological examination to ensure a homogenous
cell population of tissues. Use of human samples was approved
by the institutional review board of the University of Hong
Kong/Hospital Authority Hong Kong West Cluster (see online
supplementary materials and methods for the detailed method-
ology regarding NGS-based mutation evaluation, subsequent
data validation and functional characterisation).
RESULTS
Targeted-seq revealed recurrently mutated genes in mTOR
pathway in HCC
To explore the pattern and importance of genetic alterations in
mTOR pathway genes, we performed deep-targeted-seq in a
large cohort of 95 human HCC tumour samples (targeted-seq
cohort) for 81 mTOR pathway-related genes (see online
supplementary table S2) selected based on Kyoto Encyclopedia
of Genes and Genomes pathway deﬁnition and literature search,
with mean depth of base coverage of 154.3× (range:
135.9–197.1) (see online supplementary table S3). Normal
polymorphic sequence variants were removed by background ﬁl-
tering against reported variants deposited in public repositories.
Of the 95 human HCC tumours studied, 69 (73%) carried at
least one mutation in our selected mTOR-related gene set.
Among the 81 genes, 25 (31%) were found to be recurrently
mutated (ﬁgure 1A, upper part), while 22 (27%) were singleton
(ﬁgure 1A, lower part). The remaining 34 genes (42%) showed
no mutations in this cohort. All the mutant genes were sorted
and tabulated according to their frequency of occurrence (ﬁgure
1A) and displayed in a pathway diagram to illustrate their poten-
tial roles in the mTOR signalling (ﬁgure 1B). In order to iden-
tify the potential key signalling components frequently mutated
in HCC, we paid particular attention to the top-ranking mutant
genes. We found that six genes (and the corresponding pro-
teins), namely TSC2 (TSC2), HIF1A (HIF1α), PABPC3
(PABPC3), RB1CC1 (ATG17), RPS6KA3 (RSK2) and TSC1
(TSC1), were frequently affected in more than 5% of the cases
in our cohort (ﬁgure 1A, top left and ﬁgure 1B). The high
mutation frequency of these genes uncovered several key nodes
in mTOR pathways which, once genetically altered, may
support adaptation beneﬁt and provide survival advantage in
HCC. This might possibly involve the dysregulation of mTOR
signalling activation (TSC1/2 and RSK2), its activity coupling
with downstream biological processes including autophagy and
protein translation (ATG17 and PABPC3) and intracellular
reprogramming for the tumour microenvironment adaptation
(HIF1α). Interestingly, from our ﬁndings, mTOR kinase (2%)
and other well-known mediators and regulators such as PI3Kβ/γ
(3% and 1%), PTEN (1%) and Akt1/2/3 (1%; 1% and 1%)
were found to be mutated only in a very limited subset of the
HCC samples and no mutation was found for Rheb, which
encodes the direct downstream effector of TSC1/2.
Frequent TSC1 and TSC2 mutations deﬁned a novel
subgroup of human HCCs
Currently, no reported NGS studies in HCC have identiﬁed
these high mutation rates of TSC1 and TSC2 in HCC. Our
targeted-seq data showed that TSC2 was the top-listing mutant
gene, with mutations found in 12 of the 95 HCC tumours
(12.6%). The functionally related TSC1 mutation was also
found in 5 of the 95 tumours (5.3%) (ﬁgure 1A, upper part).
Of note, four of the ﬁve TSC1 mutants in our cohort were
found in the tumours without TSC2 mutation, thus suggesting a
mutually exclusive mutation pattern. This mutually exclusive
pattern was also observed in the other top-ranking mTOR
mutant genes like RB1CC1 and RPS6KA3 (ﬁgure 1A, upper
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part). By further retrieving and analysing the HCC exome
sequencing data (n=202) from The Cancer Genome Atlas
(TCGA) for the mTOR-related mutants, TSC2 and TSC1 were
consistently found to be most frequently mutated, affecting
5.9% and 4.95%, respectively, of the total number of cases (see
online supplementary ﬁgure S1A). TSC1 and TSC2 mutations
among different cancers were also examined using data from
TCGA cancer panel. Among the 25 cancer types being exam-
ined, 7 of them, were found to carry TSC1 and TSC2 muta-
tions, with HCC ranked second among all the cancer types.
High mutation rates of TSC1 and TSC2 in HCC and other
cancers were likely suggesting the potential involvement of
mTOR signalling dysregulation underlying their development
(see online supplementary ﬁgure S1B). In addition, we com-
pared the coincidence of TSC mutation with some of the well-
reported HCC-related mutant genes, including TP53 (p53),
CTNNB1 (β-catenin), AXIN1 (Axin1) and ARID1A (ARID1A)
(ﬁgure 2A). We found that TSC mutations were present irrespect-
ive of the genetic background of TP53 mutation. More import-
antly, TSC mutations likely stratiﬁed a novel subgroup of patients
whose tumours were not likely to be affected by CTNNB1,
AXIN1 and ARID1A mutations, in which their mutation rates
(range: 11.6%–15.8%) were comparable with TSC (ﬁgure 2B).
We further identiﬁed and conﬁrmed two additional TSC muta-
tions from our exome sequencing dataset of 16 HCC cases (see
online supplementary table S4 and supplementary ﬁgure S2). To
investigate the clinical signiﬁcance of this novel genetic subgroup
of HCC, the patient samples were stratiﬁed into three groups: (1)
with TSC mutation, (2) with known HCC driver mutation in any
of TP53, CTNNB1, AXIN1 and ARID1A but not TSC mutation
and (3) the others without the aforementioned mutations, fol-
lowed by clinicopathological correlation analysis. Intriguingly,
TSC-mutated HCCs were signiﬁcantly associated with more
aggressive tumour behaviour including larger tumour size
(p=0.034) and presence of venous invasion (p=0.041) (table 1).
This observation further provided evidence pointing to the poten-
tial tumour suppressive role of the TSC complex in human HCC.
Loss of function in TSC through genetic alteration likely contri-
butes to HCC progression by supporting tumour growth and
enhancing cancer metastasis.
Mutations in TSC1/2 rendered them functionally inactive
We conﬁrmed all the identiﬁed TSC1 and TSC2 mutations in
the tumour samples with independent Sanger sequencing
(ﬁgure 3A, B, left half of the chromatogram, see online
supplementary ﬁgure S3A,B). The majority of TSC1 and TSC2
mutations were heterozygous, with mutant read frequency at
around 50% (ﬁgure 3A, B). Thus, noisy and overlapping signals
were observed in several HCC cases carrying both copies of the
wild type and insertion/deletion (INDEL)-mutant TSC2 (see
online supplementary ﬁgure S4). On further examination of the
results in the correspondingly NTLs (ﬁgure 3A, B, right half of
the chromatogram, see online supplementary ﬁgure S3B, C),
intriguingly, among the 14 TSC2 variants in 12 HCC cases,
9 (64.3%) were somatic, while the other 5 (35.7%) were not.
Among the ﬁve TSC1 variants, two (40%) were conﬁrmed to be
somatic, while the remaining three (60%) were not. By combin-
ing the mutation data from both the validation and discovery
Figure 1 Representations of the targeted DNA sequencing (targeted-seq) for mammalian target of rapamycin (mTOR) pathway-related genes in
hepatocellular carcinoma (HCC) discovery cohort. (A) A total of 95 HBV-associated human HCC tumour samples were subjected to targeted-seq for
mTOR pathway-related genes. Sixty-nine HCC samples were found to carry at least one mTOR-related mutation. Among the 81 mTOR-related genes
being screened, 25 were found to be recurrently mutated in more than one sample, while 22 of them were singleton. The mutant genes were
ranked and listed accordingly to their frequency. (B) Schematic diagram visualising the mutants listed in (A) to illustrate their implications in
mTOR-related signalling. TSC, tuberous sclerosis complex.
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cohorts, we identiﬁed that 13 of the 111 total HCC cases
(11.7%) carried TSC2 mutations and 6 of the 111 HCC cases
(5.4%) carried TSC1 mutations (ﬁgure 3C). Overall, TSC1/2
mutations were found in a total of 16.2% (18/111) of the cases
and two-third of them (12/18) carried somatic mutations. By
considering the somatic and non-somatic variants as a whole, of
the six TSC1 variants identiﬁed, three (50%) were INDEL muta-
tions, two (33.3%) were non-synonymous ones, resulting in
single amino acid change, and the remaining one (16.7%) was
stop-gain mutation (ﬁgure 3D, right panel). The types of TSC2
mutations identiﬁed were more diverse. In addition to non-
synonymous mutations (46.7%), INDEL (20%) and two stop-
gain mutations (13.3%), splicing-related changes (20%) were also
identiﬁed in TSC2 (ﬁgure 3D, left panel). Collectively, we pre-
dicted that the identiﬁed INDEL, stop-gain and splicing-related
mutations would pose signiﬁcant deleterious effects on TSC1/2
complex and render them functionally inactive. Similarly, non-
synonymous mutations were supported by in silico prediction to
confer detrimental outcomes on native protein functions. The
TSC inactivation was achieved by limiting the key functional
domains (TSC1-binding and GTPase activating protein (GAP)
domains in TSC2; TSC2-binding domain in TSC1) and possibly
through a range of mechanisms affecting the other structural
regions in TSC1 and TSC2 proteins (ﬁgure 3E).
TSC1 and TSC2 expressions were reduced in human HCCs
carrying TSC mutations
We examined the protein expression levels of TSC1 and TSC2
in human HCCs by IHC in the 12 cases carrying somatic TSC
mutations. By scoring the intensity of TSC1 and TSC2 staining,
we demonstrated a trend (p=0.05) of downregulation in TSC
expression in human HCCs with TSC mutations, when com-
pared with the NTLs (ﬁgure 4A). Increase of S6 protein phos-
phorylation was consistently observed in representative cases
carrying somatic TSC2 mutations (ﬁgure 4B and see online
supplementary ﬁgure S5A, B). In contrast, we observed some
TSC2 expression in HCC cases carrying wild-type TSC2. More
importantly, these wild-type cases showed low phospho-S6
signals in the tumours (ﬁgure 4C). Collectively, our results
suggest that TSC2 mutations downregulates the TSC protein
expression, which in turn upregulates mTOR activity, as shown
by the increased phosphorylation of its downstream substrate.
Mutational status of TSC1 and TSC2 in HCC cell lines
Next, we examined the TSC1 and TSC2 mutational status in
HCC cell lines. On WTS of seven HCC cell lines (BEL7402,
HepG2, Hep3B, Huh7, MHCC97L, PLC and SMMC), we
found that PLC cells carried TSC2 mutation (ﬁgure 5A), which
resulted in the N1651S amino acid substitution at the
C-terminal Rap-GAP domain. This mutation was conﬁrmed by
Sanger sequencing (ﬁgure 5B, E). Immunoblotting for TSC1
and TSC2 with corresponding speciﬁc antibodies revealed
undetectable TSC1 plus a very low level of TSC2 expression in
H2P and H2M cells (a pair of HCC cell lines with different
metastatic potential established from the same patient) (ﬁgure
5C). By Sanger sequencing, we further uncovered that the
undetectable TSC1 protein expression in H2P cells were
resulted from the c.C1525T substitution which leads to the pre-
mature stop gain. In addition, H2P cell was also found to carry
a TSC2 c.A2833G substitution which leads to a K945D
Figure 2 Frequent tuberous sclerosis complex (TSC)1 and TSC2 mutations deﬁne a novel subgroup of human hepatocellular carcinomas (HCCs).
(A) Diagram listing the key genes found to be mutated in our HCC discovery cohort (n=95). TP53, CTNNB1, AXIN1 and ARID1A are key genes which
have been known to be mutated in human HCC. We found that the TSC1 and TSC2, which encodes protein complex as negative regulator of
mammalian target of rapamycin signalling, were frequently mutated. (B) Venn diagrams showing the rates of coincidence of TSC2 or TSC1
mutations with TP53, CTNNB1, AXIN1 and ARID1A as highlighted by the black lines.
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mutation at the centre region of TSC2 (ﬁgure 5E). Taken
together, we found that two of the eight HCC cell lines (25%)
showed TSC1 and TSC2 mutations.
mTOR Inhibitor effectively suppressed cell proliferation in
TSC-mutant HCC cells
Loss-of-function mutation of TSC1/2 relieves Rheb G-protein
from inactivation and leads to hyperactivation of mTORC1 activ-
ity. We sought to ﬁnd out the functional implications of TSC
mutation in HCC regarding to the tumour sensitivity towards
mTOR inhibitor treatment. Eight HCC cell lines with well-
deﬁned TSC1/2 mutation status were plated and subjected to
rapamycin treatment at three different concentrations ranging
between 1, 10 and 100 nM (ﬁgure 5F) for 4 days. Among the six
HCC carrying wild-type TSC1/2, three of them (Huh7, 97L and
HepG2) were sensitive to rapamycin treatment starting from
10 nM, while the remaining three (SMMC, BEL7402 and
Hep3B) were insensitive even at the highest concentration.
Interesting, for PLC and H2P cells carrying TSC1/2 mutations,
their proliferation was marked suppressed by rapamycin treat-
ment at the minimal dosage. The hypersensitivity to the low
mTOR inhibitor treatment supports the idea that TSC1/2 muta-
tion may serve as a potential biomarker to assess the reliance of
HCC cells on mTOR signalling and predicts their responsiveness
to mTOR inhibitor treatment. To further evaluate and mimic the
effect of restoration of TSC2 expression in HCC cells, we stably
knocked down Rheb in TSC2 wild-type SMMC cells and
TSC2-mutant PLC cells by lentiviral-based small hairpin (sh)
RNA approach (see online supplementary ﬁgure S6A, B).
Although stable shRheb SMMC cells could be established (see
online supplementary ﬁgure S6C), on the contrary, stable shRheb
PLC cells could not be established after lentiviral transduction
and subsequent puromycin selection. It was likely that TSC2
mutation renders PLC cells to be Rheb-dependent and expression
of shRNA against Rheb drastically suppressed its proliferation
(see online supplementary ﬁgure S6D).
TSC2 mutation-bearing HCCs were hyper-responsive to
mTOR inhibitor in PDTX model
To further recapitulate our in-vitro observation, we used two of
our HCC PDTX models who carried biologically relevant TSC2
stop-gain mutations (PDTX#5: TSC2 Q1377X and PDTX#9:
TSC2 Q63X) and a PDTX with wild-type TSC2 (PDTX#3) as
the control. The PDTX models were subjected to rapamycin
treatment daily and the body weight and tumour size were mon-
itored. Rapamycin treatment at a concentration of 1.0 and
2.5 mg/kg was both well tolerated, as the body weights of the
treatment group were similar to those of the vehicle control
(ﬁgure 6A). Rapamycin at either 1.0 or 2.5 mg/kg was sufﬁcient
to almost completely suppress tumour growth in PDTX#5
(ﬁgure 6B, left panel). We then used rapamycin at 1.0 mg/kg as
the working concentration. Both PDTX#9 (ﬁgure 6B, middle
panel) and PDTX#5 (ﬁgure 6B, right panel) showed a similar
remarkable tumour-suppressive response with rapamycin. In
contrast, in PDTX#3 with wild-type TSC2, the rapamycin-
treated tumours increased in volume progressively, though mod-
erately (ﬁgure 6B, right panel). As an indication of poorer
response towards rapamycin treatment, the relative tumour
volume (rapamycin: vehicle) of PDTX#3 was signiﬁcantly
higher than those of PDTX#5 and PDTX#9, starting from day
12 onwards (t-test, p<0.001) (ﬁgure 6C). A greater difference
in tumour size between the vehicle-treated and rapamycin-
treated tumours (ﬁgure 6D) as well as a higher mean tumour
mass ratio (vehicle:rapamycin) was seen in both PDTX#5 and
PDTX#9, as compared with PDTX#3 (ﬁgure 6E). Interestingly,
very small tumours with nearly negligible tumour mass were
observed in rapamycin-treated tumours in PDTX#5 and
PDTX#9 but not PDTX#3. The hyper-sensitivity towards
mTOR inhibitor treatment was further supported by the signiﬁ-
cantly lower relative tumour mass (rapamycin/vehicle) of
PDTX#5 and PDTX#9 when compared with PDTX#3 (t-test,
p<0.001) at the end point of experiment (ﬁgure 6F). Taken
together, our results suggested an overall treatment beneﬁt with
the use of mTOR inhibitor in HCC and the treatment response
was superior especially in those tumours which bore mutations
leading to the activation in this pathway. These observations
demonstrated and suggested the therapeutic implication and
translational potential of the identiﬁed TSC1/2 mutants in
human HCCs.
Table 1 Clinicopathological correlation of patient with HCC
samples carrying TSC mutation and other background mutation*
Parameters
With TSC
mutation
(n=18)
With known
HCC driver
mutation†
(n=53)
Others
(n=40) p Value‡
Gender
Male 15 (83.3%) 40 (75.5%) 26 (65%) 0.342
Female 3 (16.7%) 13 (24.5%) 14 (35%)
Mean age
(range)§
50.7 (24–68) 52.4 (29–72) 51.0 (24–74) 0.812
Tumour size
>5 cm 15 (83.3%) 31 (58.5%) 19 (47.5%) 0.034
≤5 cm 3 (16.7%) 22 (41.5%) 21 (52.5%)
Background liver disease
Normal 0 (0%) 0 (0%) 3 (7.5%) 0.350
Chronic
hepatitis
8 (44.4%) 22 (41.5%) 17 (42.5%)
Cirrhosis 10 (55.6%) 31 (58.5%) 20 (50%)
Liver invasion
Yes 4 (23.5%) 23 (45.1%) 10 (26.3%) 0.117
No 13 (76.5%) 28 (54.9%) 28 (73.7%)
Tumour microsatellite formation
Yes 9 (52.9%) 29 (55.8%) 20 (51.3%) 0.912
No 8 (47.1%) 23 (44.2%) 19 (48.7%)
Tumour encapsulation
Yes 5 (27.8%) 18 (34.6%) 15 (39.5%) 0.712
No 13 (72.2%) 34 (65.4%) 23 (60.5%)
Venous invasion
Yes 14 (77.8%) 31 (58.5%) 17 (42.5%) 0.041
No 4 (22.2%) 22 (41.5%) 23 (57.5%)
Cellular differentiation
Edmondson
grade I–II
5 (27.8%) 21 (39.6%) 15 (37.5%) 0.724
Edmondson
grade III–IV
13 (72.2%) 32 (60.4%) 25 (62.5%)
TNM staging
I–II 4 (22.2%) 19 (35.8%) 19 (47.5%) 0.175
III–IV 14 (77.8%) 34 (64.2%) 21 (52.5%)
Bold indicates statistically significant p values.
*Patient samples from discovery and validation cohorts (n=111) were stratified into
three groups: with TSC mutation (n=18), with known HCC driver mutations (n=53)
and other mutations (n=40) accordingly.
†Cases that carry no TSC mutations but having mutations in any of TP53, CTNNB1,
AXIN1 and ARID1A.
‡Fisher’s exact test.
§Analysis of variance.
HCC, hepatocellular carcinoma; TNM, tumour, node, metastases; TSC, tuberous
sclerosis complex.
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DISCUSSION
Despite mutations have been recurrently detected in genes
responsible for cell cycle regulation (TP53), cell proliferation
(CTNNB1) and switch/sucrose non-fermentable (SWI/SNF)
ATP-dependent chromatin remodelling (ARID1A), consensus
among mutations or mutant genes detected in recently performed
NGS-based studies is suboptimal. High genetic heterogeneity
remains the greatest challenge for the delineation of HCC
molecular mechanisms. Based on evidence extracted from our
NGS-based datasets, extensive components of mTOR signalling
cascade are mutated in human HCCs. These data provide novel
insight in suggesting signiﬁcant mutation-dependent regulation
mechanism on mTOR signalling, with multiple key and canonical
mTOR pathway-related components being shortlisted and con-
ﬁrmed to harbour frequent mutational disruptions. These gene
targets are attractive and potentially promising targets for further
investigations to further understand the underlying mechanistic
processes in driving mTOR hyperactivation.
PI3K/Akt/mTOR pathway has recently drawn great attention
as an alternative therapeutic, druggable pathway in HCC to
enhance the limited survival advantage delivered by sorafenib
treatment. Our group and others have previously demonstrated
the overexpression of mTOR in more than 50% of the
HCCs.6 8 mTOR Signalling is tightly regulated by upstream sig-
nalling in response to extracellular growth factor, stresses and
nutrients. The signalling axis is dually regulated by both phos-
phatase and tensin homolog (PTEN) and TSC1/2. We had previ-
ously shown that PTEN expression was downregulated in our
HCCs from patients and the downregulation was associated
with increased invasive behaviour in HCC.9 Intriguingly, our
targeted-seq data further revealed that PTEN was rarely
mutated in HCC (identiﬁed only in a single case among the 95
patient samples). In the current study, we identiﬁed a common
mechanism in a subset of patients with HCC carrying TSC
mutations, which predispose them to have deregulated mTOR
activity. Currently, very limited information is known about the
expression of TSC1 and TSC2 in human HCCs. A single brief
report used IHC to demonstrate the under-expression of TSC2
in human HCCs. The under-expression was also found to be
associated with advanced tumour stage, vascular invasion and
Figure 3 Representations of the conﬁrmation of tuberous sclerosis complex (TSC)1/2 mutations and their possible effects in negatively regulating
their tumour suppressing activity. (A) Sanger sequencing conﬁrmation of the TSC2 mutations identiﬁed from the targeted DNA sequencing
(targeted-seq) in both tumours and corresponding non-tumorous livers is shown. The identiﬁed mutations were classiﬁed as somatic and
non-somatic. (B) Sanger sequencing conﬁrmation of the TSC1 mutations identiﬁed from the targeted-seq in both tumours and corresponding
non-tumorous livers is shown. The identiﬁed mutations were classiﬁed as somatic and non-somatic. (C) Flow chart summarising the number of
hepatocellular carcinoma (HCC) cases carrying the TSC1 and TSC2 mutations in the discovery cohort, validation cohort or the total combined HCC
cases. (D) Diagram summarising and categorising the types of TSC2 (n=15) and TSC1 (n=6) mutations found in the current study. (E) Schematic
diagram showing the alterations of the amino acid changes in TSC1 and TSC2 by the identiﬁed genetic changes.
6 Ho DWH, et al. Gut 2016;0:1–11. doi:10.1136/gutjnl-2016-312734
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Figure 4 Downregulation of tuberous
sclerosis complex (TSC)1/2 expression
in human hepatocellular carcinoma
(HCC) carrying TSC mutations is
shown. (A) Twelve HCC samples
carrying somatic TSC1/2 mutations and
their corresponding NTL were
subjected to IHC staining for TSC1/2.
The TSC1/2 staining intensity in the
tumour and non-tumour tissues were
collectively presented as mean IHC
score. Their statistical difference was
compared by Wilcoxon signed-rank test
(one-sided). (B) Representative IHC
images showing the reduced TSC2
expression in HCC tumours carrying
TSC2 non-sense mutation (TSC2 Q63X,
Case PY003T) and splicing mutation
(Case 330T) and their corresponding
phospho-S6 staining as downstream
markers for mammalian target of
rapamycin pathway activation. (C)
Representative IHC images showing
the TSC2 expression and the
downstream phospho-S6 staining in
two HCC cases (TSC2 WT, Case 361T
and Case 368T) with no TSC2
mutation. IHC, immunohistochemistry;
NTL, non-tumorous liver.
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poor prognosis.10 The inactivation of TSC1/2 complex has been
found to be signiﬁcantly relevant to HCC development, as ele-
gantly demonstrated by the liver-speciﬁc TSC1 knockout mouse
model.11 12 Menon et al have demonstrated that about 80% of
the TSC1-null livers developed spontaneous tumours at the age
of 9–10 months and 50% of them resembled HCC. HCC for-
mation in TSC1 knockout was found to be a result of chronic
mTORC1 activation. The involvement of the chronic mTORC1
Figure 5 The mutational status and expression of tuberous sclerosis complex (TSC)1/2 in a panel of human hepatocellular carcinoma (HCC) cell
lines and their sensitivity to mammalian target of rapamycin inhibitor treatment are shown. (A) RNA sequencing revealed that PLC HCC cells carried
a TSC2 mutation. (B) The TSC2 mutation identiﬁed by RNA sequencing in PLC was conﬁrmed by Sanger sequencing at genomic level. (C) Protein
expression levels of TSC1 and TSC2 in a panel of HCC cell lines were determined by western blotting with the use TSC1-speciﬁc and TSC2-speciﬁc
antibodies. PLC, H2P and H2M cells showed relatively low TSC1 as well as TSC2 protein expression. H2M was derived from H2P. (D) Sanger
sequencing revealed a stop-gain mutation in TSC1 and a missense mutation in TSC2 in H2P cells. The stop-gain mutation may account for the loss
of TSC1 protein expression in H2P cells. (E) Schematic diagram showing the TSC1 and TSC2 mutants identiﬁed in PLC and H2P cells. (F) Eight HCC
cell lines with deﬁned mutational status of TSC1/2 were subjected to rapamycin treatment at the indicated concentrations for 4 days, followed by
ﬁxation and crystal violet staining for visualisation.
8 Ho DWH, et al. Gut 2016;0:1–11. doi:10.1136/gutjnl-2016-312734
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kinase activity was further supported by the effective blocking
of the TSC1-null tumour formation with the early administra-
tion of rapamycin at the age of 5 months before the appearance
of macroscopic lesion.12
In the current study, somatic mutations were detected in
known HCC genes including TP53, CTNNB1, AXIN1 and
ARID1A, revealing the signiﬁcant involvement of genomic aber-
rations in the relatively better-characterised genes of HCC. In
addition, various key components of the mTOR pathway were
identiﬁed to be altered by somatic mutations, which highlighted
its potential importance and possible translational implication
through intervention with the use of mTOR inhibitor in suscep-
tible mutant patients. Based on frequency as well as the clinico-
pathological correlation, TSC mutation may likely represent a
major single driving factor in hepatocarcinogenesis, which
confers at least comparable effect to known HCC drivers such
as TP53, CTNNB1, AXIN1 and ARID1A.
The study reported by Schulze et al13 and Totoki et al14 are
currently the latest and largest one, among the reported
NGS-based mutation screening studies. Their ﬁndings are based
on NGS data of 243 cases and 503 cases, respectively. However,
HBV infection only accounted for up to a quarter of their cases
while our cohorts were entirely HBV-positive. With our study
focusing entirely on HBV-associated HCC, homogeneity of the
aetiology hopefully could empower us to achieve better
intra-study consensus, given our limited sample size. We believe
such difference in the underlying aetiological risk factor may
likely be responsible for the apparently higher frequency of TSC
mutations detected in our cohorts. Such frequent disruption
(>15%) on TSC regulation of mTOR activity probably suggests
a profound effect of mTOR activation by TSC disruption in
HBV-associated hepatocarcinogenesis. Intriguingly, in echo with
our current ﬁndings, we noted two recent studies highlighting
the importance of mTOR signalling in HCC. Janku et al15
reported a mutation screening on a conﬁned panel of 182
cancer-related genes. More recently, another study concurrently
highlighted the hyperactivation of mTOR signalling in hepato-
carcinogenesis. Based on a seemingly retrospective approach in
explaining their available clinical trial data on mTORC1 inhibi-
tor everolimus, they provided explanatory data pinpointing on
TSC2 loss-of-function leading to elevated mTOR signalling.16
More importantly, using HCC cell lines and xenografts, they
demonstrated sensitivity to everolimus according to TSC2 status
as assayed by IHC. Their sample collection of Asian
HBV-positive HCCs (∼20%) frequently identiﬁed TSC2 loss
and such patients receiving everolimus tended to have longer
overall survival than those receiving placebo. In spite of their
nice work in highlighting the therapeutic and prognostic value
TSC2, the mechanism underlying TSC2 loss in HCC remains
unclear. Beyond what they have reported, our current ﬁndings
Figure 6 Hepatocellular carcinoma (HCC) patient-derived tumour xenograft (PDTX) models with tuberous sclerosis complex (TSC)2 mutations were
more sensitive to mammalian target of rapamycin inhibitor treatment. (A) The graph showing body weight of TSC2-mutant (PDTX#5 and PDTX#9)
and TSC2 wild-type (PDTX#3) PDTX tumour-bearing mice throughout the treatment. Body weights were measured every 3 days to assess the general
toxicity of the injected vehicle and rapamycin. The relative body weights (rapamycin/vehicle) of PDTX#5, PDTX#9 and PDTX#3 mice are shown. (B)
The tumour volumes of the PDTX tumour-bearing mice subjected to vehicle or rapamycin treatment at 1.0 mg/kg/day, unless stated otherwise, are
shown. The volumes of the subcutaneous tumours were measured every 3 days throughout the treatment. The numbers in grey represent the mean
volume ratio between the vehicle and rapamycin-treated group at the indicated time points. t-test; *p<0.05, **p<0.01; ***p<0.001. (C) The
relative tumour volumes (rapamycin/vehicle) of PDTX#5 and PDTX#9 tumours are shown alongside with those of PDTX#3. t-test; ***p<0.001. (D)
An overview of the subcutaneous tumours formed and the corresponding dissected tumours at the end point of the experiment is shown. (E) The
tumour masses of the dissected tumours at the end point of the treatment are shown. The numbers in grey represent the mean tumour mass ratio
between the vehicle and rapamycin-treated groups. t-test; *p<0.05, **p<0.01; ***p<0.001. (F) The relative tumour masses (rapamycin/vehicle) of
PDTX#5, PDTX#9 and PDTX#3 are shown. t-test; **p<0.01; ***p<0.001.
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systematically delineated the comprehensive mutational land-
scape for mTOR signalling genes and discovered frequent muta-
tions in TSC1/2 on regulating mTOR signalling. The high
frequency of TSC mutations has provided key and novel explan-
ation in addressing the underlying molecular mechanism for the
TSC loss in hyperactivation of mTOR signalling. We further
demonstrated, through PDTX models carrying TSC2-inactivating
mutations, that hyperactivation of mTOR signalling via muta-
tional disruption of TSC regulation is sensitive to rapamycin
treatment. PDTXs are established by implanting primary
tumours into immunodeﬁcient mice. It provides better con-
servation and representation of natural tumour heterogeneity
and architecture to physiological human tumour. With the
use of PDTX model, ﬁndings of preclinical testing on drug
response will be more relevant and predictive than traditional
cancer cell line model.17 Through the perfect combination of
both high-throughput NGS-based mutation screening and
PDTX model, our study demonstrates, with necessary sup-
portive evidence correlating mutational ﬁndings with corre-
sponding drug testing, the potential personalised treatment
on relevant patients with HCC carrying speciﬁc molecular
alterations. These preclinical ﬁndings open up the possibility
for using rapamycin or its subsequent derivatives as an alter-
native or in complement with sorafenib in treating speciﬁc
mTOR hyperactivated patients. We believe TSC mutations
represent one of the major and previously undocumented
mechanisms in leading to mTOR hyperactivation in
HBV-associated HCC. Nevertheless, we strongly agree that
mTOR inhibition is likely to be a rational therapeutic option
for patients demonstrating mTOR hyperactivation, regardless
of its underlying mechanism. Therefore, the treatment efﬁ-
cacy of mTOR inhibition treatment would be greatly
improved with further exploration and establishment of the
stratiﬁcation strategy on mTOR hyperactivation status not
limited to TSC mutation.
In summary, our study has substantiated the signiﬁcance of
mTOR signalling in HCC through evidence pinpointing its
novel mutational aspect with mutant genes recurrently spotted
in multiple cases as well as critical mutants in multiple pathway
components. Our ﬁndings imply the potentially profound
involvement of mTOR signalling in HCC and draw further
attention on personalised therapeutic option for a novel molecu-
lar subset of patients with susceptible mutant HCC, through the
inhibition of mTOR signalling.
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